The Role of the FTO Gene in Reward System Activation in Obese and Healthy Subjects

NCT ID: NCT01863212

Last Updated: 2013-05-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

500 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-09-30

Study Completion Date

2014-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In order to investigate if individuals, carrying genetic variants predisposing to obesity, respond differently to visual presented food images than non-carriers the investigators aim to screen 500 people for a common risk variant in the FTO gene. From those 500 screened 40 subjects, 20 homozygous for the risk allele and 20 homozygous for a non risk allele will be selected for the second step in the study. This part involves the fMRI technique to visualize the brain response, focus on reward system activation, when food images are visually presented in the scanner. Factors regarding eating behavior, sleep, physical exercise and relation to food are investigated in the first part of the study as well as clinical parameters such as BMI.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity Eating Behavior

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Risk allele carriers

Individuals homozygous for the risk allele (A/A) The interventions administrated to this group: 'Blood sampling for genetic analyse', 'Stroop test', 'fMRI'

Group Type EXPERIMENTAL

Blood sampling for genetic analyse

Intervention Type PROCEDURE

Blood sampling are performed at the initiation visit in order to screen for allele variants

Stroop test

Intervention Type BEHAVIORAL

Selective attention test where subjects, in one minute, names the ink color of several words without naming the word itself.

fMRI

Intervention Type OTHER

Functional Magnetic Resonance Imaging, performed to view brain activity

Non risk allele carriers

Individuals homozygous for the non-risk allele (T/T) The interventions administrated to this group: 'Blood sampling for genetic analyse', 'Stroop test', 'fMRI'

Group Type EXPERIMENTAL

Blood sampling for genetic analyse

Intervention Type PROCEDURE

Blood sampling are performed at the initiation visit in order to screen for allele variants

Stroop test

Intervention Type BEHAVIORAL

Selective attention test where subjects, in one minute, names the ink color of several words without naming the word itself.

fMRI

Intervention Type OTHER

Functional Magnetic Resonance Imaging, performed to view brain activity

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood sampling for genetic analyse

Blood sampling are performed at the initiation visit in order to screen for allele variants

Intervention Type PROCEDURE

Stroop test

Selective attention test where subjects, in one minute, names the ink color of several words without naming the word itself.

Intervention Type BEHAVIORAL

fMRI

Functional Magnetic Resonance Imaging, performed to view brain activity

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* No medications (except contraceptives including estrogen)
* No metabolic disorders/diseases
* Right handed
* Color vision
* Normal sleep-wake rhythm (eg. shift workers can not participate)

Exclusion Criteria

* Specific preferences of food, for example vegetarians
* Grandparents originating from country outside the Nordic area
* Metallic implants
Minimum Eligible Age

18 Years

Maximum Eligible Age

37 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Uppsala University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Christian Benedict, PhD

Role: PRINCIPAL_INVESTIGATOR

dep. Neuroscience, Uppsala University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Uppsala University

Uppsala, Uppsala County, Sweden

Site Status RECRUITING

dep. Neuroscience, Uppsala University

Uppsala, Uppsala County, Sweden

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Sweden

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Christian Benedict, PhD

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Role: primary

Christian Benedict, PhD

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Andreoli MF, De Francesco PN, Titova OE, Perello M, Schioth HB. Plasma LEAP2 concentration is associated with attention and cognitive responses to low-calorie food cues in men depending on body weight status. Physiol Behav. 2025 Nov 1;301:115049. doi: 10.1016/j.physbeh.2025.115049. Epub 2025 Aug 7.

Reference Type DERIVED
PMID: 40759193 (View on PubMed)

Wiemerslage L, Islam R, van der Kamp C, Cao H, Olivo G, Ence-Eriksson F, Castillo S, Larsen AL, Bandstein M, Dahlberg LS, Perland E, Gustavsson V, Nilsson J, Vogel H, Schurmann A, Larsson EM, Rask-Andersen M, Benedict C, Schioth HB. A DNA methylation site within the KLF13 gene is associated with orexigenic processes based on neural responses and ghrelin levels. Int J Obes (Lond). 2017 Jun;41(6):990-994. doi: 10.1038/ijo.2017.43. Epub 2017 Feb 14.

Reference Type DERIVED
PMID: 28194012 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

LSF008786

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Brain Function and EEG
NCT05003076 COMPLETED EARLY_PHASE1